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Abstract
In recent years, a marked increase in the incidence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has
occurred in many countries. This review addresses the effectiveness and limitations of drugs classically used for the treatment of MRSA,
e.g. vancomycin, and also newer anti-MRSA antimicrobials, e.g. second-generation glycolipopeptides, tigecycline, and b-lactams.
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Alternatives to Classically Used Drugs
Vancomycin
Vancomycin has been, and still is, the mainstay of therapy for
methicillin-resistant Staphylococcus aureus (MRSA) infections
for more than 50 years, but treatment failures are frequently
reported [1–6]. Vancomycin has worse clinical results than
b-lactam drugs in treating infections caused by strains sus-
ceptible to both [2,3,5,7,8]. The intrinsic limitations of vanco-
mycin include poor tissue penetration, particularly in the
lung, relatively slow bacterial killing, and toxicity.
Fully vancomycin-resistant strains (vancomycin-resistant
S. aureus (VRSA)) remain rare. These strains have so far had
limited clinical consequences, not having been associated
with invasive disease [9–11]. They have been isolated mainly
in patients simultaneously infected by, or colonized with,
MRSA and vancomycin-resistant enterococci.
Vancomycin-intermediate S. aureus (VISA) strains were ini-
tially reported from Japan by Hiramatsu et al. in 1996 [12].
VISA strains, deﬁned by an MIC of vancomycin of 4–8 mg/L,
represent less than 1% of all S. aureus strains isolated
throughout the world. These isolates are murein hyperpro-
ducers. Owing to the limited tissue penetration of vancomy-
cin, patients infected with these strains have a poor
response to this drug. When only a proportion of a strain of
S. aureus is vancomycin-intermediate, the strain is called ‘het-
ero-VISA’. Hetero-VISA isolates are more common than
VISA isolates, and are purportedly more difﬁcult to treat
than fully susceptible isolates [5,13].
There is growing concern that vancomycin is losing activ-
ity for MRSA infections. So-called ‘vancomycin creep’ is
deﬁned as a progressive increase in the MICs for isolates of
S. aureus, with strains remaining susceptible but at the high
end of the CLSI susceptibility range [14]. This creep has been
observed in some [1,15–18], but not all [19,20], institutions.
In 2006, vancomycin MIC breakpoints for S. aureus were
lowered, resulting in an increase in the proportion of strains
considered to be resistant (Table 1). This decision reﬂected a
growing amount of microbiological and clinical data indicating
that isolates of S. aureus are less likely to respond to vancomy-
cin therapy when MICs are >1 mg/L [16,21]. For example,
Soriano et al. from Spain reported increased mortality associ-
ated with MRSA bacteraemia when vancomycin was empiri-
cally used for the treatment of infection due to strains with a
vancomycin MIC >1 mg/L [22]. Although there is disagree-
ment on the best laboratory method with which to determine
the in vitro susceptibility of these isolates, microbiology labora-
tories should report numerical MICs for isolates of S. aureus
obtained from clinically signiﬁcant infections.
Patients with infections caused by strains with a vancomy-
cin MIC >1 mg/L can be managed by the combination of
vancomycin with other drugs or by doses of vancomycin high
enough to achieve troughs >15 mg/L[23]. However, the risk
of higher dosages is an increase in nephrotoxicity.
One alternative approach is to administer vancomycin
with rifampin [24], a common clinical practice in many
institutions. However, the in vitro data regarding the superi-
ority of this combination are contradictory [25–27], and
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information from animal models [28,29] or humans is insufﬁ-
cient for us to conclude that adding rifampin to vancomycin
for the treatment of MRSA isolates is always superior to the
administration of vancomycin alone [24,30,31]. Some results
suggest that the potential for hepatotoxicity, drug–drug
interactions, and the emergence of resistant S. aureus isolates
warrants a careful risk–beneﬁt assessment before rifampin is
added to standard antimicrobial treatment for severe
S. aureus infections [32,33].
Using a different approach, models have suggested that a
single dose or a very short course of gentamicin added to
vancomycin may maximize synergistic and bactericidal activity
and minimize toxicity in therapy for isolates of S. aureus with
a gentamicin MIC of <500 mg/L, but not for highly gentami-
cin-resistant isolates [34–38]. A combination of vancomycin
and gentamicin should be used carefully in patients with
MRSA infections, and only for a very short period of time,
to avoid nephrotoxicity [39–46].
Linezolid
Linezolid is the ﬁrst of the oxazolidinones, a new class of
antimicrobial agents. Linezolid inhibits protein synthesis at
the ribosome level, and may have a bactericidal or bacterio-
static effect, depending on the circumstances [47–50].
Linezolid is active in vitro against most Gram-positive bac-
teria, including methicillin-susceptible S. aureus (MSSA) and
MRSA [51–54]. There have been anecdotal reports of resis-
tance of MRSA to linezolid [55–61].
Linezolid is highly bioavailable after oral administration
(more than 90%), and can be administered intravenously
[62]. The volume of distribution is approximately 20 L,
protein binding is 31%, and the half-life is 6 h. Linezolid is
largely metabolized in the liver, and 30% of the drug is
eliminated unchanged in the urine. Linezolid requires no
dosing adjustments in cases of either renal or hepatic failure
[63–71].
Linezolid is generally well tolerated, but myelotoxicity and
neurotoxicity are the major adverse events. Myelotoxicity is
mainly expressed as thrombocytopenia in patients with more
than 14 days of treatment, predominantly occurring in indi-
viduals with pre-existing myelosuppression or receiving drugs
that are also myelotoxic. Lactic acidosis, peripheral neuro-
pathy, and optic neuropathy are very uncommon but
potentially irreversible adverse consequences of linezolid use.
These complications may occur in patients with long-term
use of the drug, and its use is therefore presently restricted
to a maximum of 4 weeks [72–78].
Linezolid has been approved for the treatment of commu-
nity and nosocomially acquired pneumonia and skin and soft
tissue infections (SSTIs). The clinical trials included cases
caused by MRSA. Information regarding the use of linezolid
in the treatment of bacteraemia, catheter-related blood-
stream infections (CR-BSIs) and infective endocarditis (IE) is
limited [79–82].
Linezolid is probably the drug of choice for the treatment
of patients with ventilator-associated pneumonia (VAP)
caused by MRSA. Each of three comparative studies showed
non-inferiority of linezolid to vancomycin in the treatment of
VAP [83–85]. A summary study combining the patients
enrolled in two of the three trials signiﬁcantly favoured lin-
ezolid in the Gram-positive and MRSA subsets. Logistic
regression showed that linezolid was an independent predic-
tor of survival, with ORs of 1.6 for all patients, 2.6 for
Gram-positive VAP, and 4.6 for MRSA VAP [86].
In hospitalized patients with community-acquired pneumo-
nia (CAP), empirical linezolid was more effective than ceftri-
axone/cefpodoxime, with comparable cure rates in
Steptococcus pneumoniae pneumonia and higher cure rates in
pneumonia complicated by bacteraemia [87]. Linezolid could
also be considered an alternative to vancomycin for treating
serious infections caused by antimicrobial-resistant Gram-
positive cocci in children [88].
Linezolid has also been approved for the treatment of
complicated SSTIs (cSSTIs). In a randomized, double-blind,
multicentre trial, linezolid was compared to oxacillin–dicloxa-
cillin in patients with cSSTIs. The clinical cure rates were
69.8% and 64.9%, and the microbiological cure rates were
88.1% and 86.1%, in the linezolid and oxacillin–dicloxacillin
groups, respectively. No serious drug-related adverse events
were reported in the linezolid group [89]. In MRSA cSSTI
infections, treatment with linezolid permits an earlier hospital
discharge than treatment with vancomycin [90,91].
A study comparing the empirical use of linezolid and
comparators for the treatment of patients suspected of
CR-BSIs reported a higher mortality rate in the linezolid
arm, due to Gram-negative superinfections. However, in
patients with documented Gram-positive infections, linezolid
was not inferior to comparators. This study [92] indicates
that in patients with suspected CR-BSIs, empirical coverage
against Gram-negative bacteria is always important until
microbiological reports permit speciﬁc pathogen-directed
therapy.
TABLE 1. Old and new breakpoints of Staphylococcus aureus
for vancomycin susceptibility
Susceptible
(mg/L)
Intermediate
(mg/L)
Resistant
(mg/L)
Old £4 8–16 ‡32
New £2 4–8 ‡16
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Linezolid is being used in other clinical situations in which
further clinical trials are required to clarify its role.
Linezolid is a potentially useful drug for the treatment of
patients with bone and joint infections due to MRSA.
Adverse events associated with long-term use, such as bone
marrow suppression and peripheral neuropathy, are the main
issue [93–106].
Linezolid has been used successfully in the treatment of
many cases of IE caused by resistant Gram-positive cocci.
However, the studies are largely case reports, and many cases
were failing with other drugs or were cases in which linezolid
was introduced sequentially after other primary therapy. The
use of a bacteriostatic antimicrobial for treatment of IE
remains contrary to classic principles [81,107,108].
Linezolid has been used occasionally for the treatment of
central nervous system infections, including meningitis and
brain abscesses. In animal experimental models, the drug has
shown good intraspinal cerebrospinal ﬂuid (CSF) penetration.
Linezolid has been used successfully as salvage therapy in
cases of bacterial meningitis [109–118], ventriculitis [119–
122], and even brain abscess [123].
Overall, linezolid is, at least, not inferior to vancomycin
for the treatment of MRSA infections [49].
Co-trimoxazole
The potential role of folate antagonists, including trimetho-
prim–sulphamethoxazole, in the treatment of MRSA infec-
tions has been recently reviewed by Proctor et al. [124] and
Grim et al. [125]. Sulfonamides are bacteriostatic against
S. aureus by inhibiting dihydropteroate synthase and blocking
folate biosynthesis. A second step in the inhibition of folate
biosynthesis is carried out by trimethoprim, a tetrahydro-
folate reductase inhibitor. The availability of exogenous
thymidine may inactivate trimethoprim–sulphamethoxazole,
as it bypasses the double biosynthetic blockade.
A high proportion of MRSA isolates susceptible to tri-
methoprim–sulphamethoxazole has been recently reported
in different settings [126–128]. In the last nationwide study
of S. aureus strains isolated in Spain, trimethoprim–sulpha-
methoxazole was active in vitro against almost 98% of all
MRSA isolates [129,130].
Data on the treatment of MRSA with trimethoprim–sul-
phamethoxazole in animal models are contradictory, and the
results may depend on the moment at which treatment is
instituted and the liberation of thymidine from necrotic
tissues [131].
The role of trimethoprim–sulphamethoxazole in the treat-
ment of MRSA infections has been reviewed by Grim et al.
[125]. In a randomized, prospective trial comparing trimetho-
prim–sulphamethoxazole with vancomycin [132] in intrave-
nous drug users with endovascular infections caused by
MSSA or MRSA (47% MRSA), trimethoprim–sulphamethox-
azole was inferior to vancomycin in terms of duration of
bacteraemia (6.7 vs. 4.3 days), sterilization of wound cultures
(5.8 vs. 3.8 days), duration of fever, and failure rates
(6/43 with trimethoprim–sulphamethoxazole vs. 1/58 with
vancomycin).
For SSTIs, treatment with trimethoprim–sulphamethoxaz-
ole was compared with treatment with doxycycline in an
area of high prevalence of MRSA. The overall clinical failure
rate was 9%, with all failures occurring in the trimethoprim–
sulphamethoxazole group [133].
The incidence of nosocomial pneumonia may be decreased
by the prophylactic use of trimethoprim–sulphamethoxazole
[134].
The value of adding rifampin to trimethoprim–sulphameth-
oxazole requires further investigation.
Trimethoprim–sulphamethoxazole, in summary, is a sec-
ond-line agent for the treatment of severe MRSA infections
in patients unable to receive more active drugs, such as gly-
copeptides or linezolid. If trimethoprim–sulphamethoxazole
is selected, intravascular infections, and infections with
abscesses or a high degree of necrotic tissue, must be
avoided. Infections with low bacterial burden, as is the case
in chronic osteomyelitis, and with no risk of death in case of
clinical failure are better candidates for trimethoprim–sulpha-
methoxazole treatment [135].
Fusidic acid
Fusidic acid is derived from the fungus Fusidium coccineum,
and was released for clinical use in the 1960s. The drug is
available, at least in Europe and Australia, but not in the USA.
Fusidic acid as an alternative for the treatment of MRSA has
been extensively reviewed by Howden and Grayson [136].
Fusidic acid remains active in vitro against many strains of
MSSA and MRSA, including hetero-VISA and VISA strains
[137–139]. Between 1999 and 2005, more than 95% of 240
MRSA isolates in a Canadian hospital were susceptible to
fusidic acid [139,140]. Resistance is generally deﬁned as an
MIC of ‡2 mg/L or as a zone (for a 2.5-lg disk) ‡22 mm.
The prevalence of resistance of S. aureus to fusidic acid
worldwide is highly variable, but overall is close to 5% [141].
In countries with higher rates, the spread of one or a few
clones is usually responsible.
Fusidic acid inhibits the polypeptide elongation stage of
bacterial protein synthesis. It is bacteriostatic at low concen-
trations and potentially bactericidal at higher concentrations
[142].
The combination of fusidic acid with rifampin or b-lactams
may be synergistic in certain circumstances, and this appears
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to be associated with lower rates of development of fusidic
acid resistance [138,143,144].
Fusidic acid is available in intravenous, oral and topical
preparations, and has good tissue distribution, including
bone, prostate, and abscesses [145,146].
Owing to good oral absorption, fusidic acid may be partic-
ularly useful for the ambulatory treatment of MRSA infec-
tions for which there are no better oral alternatives, such as
trimethoprim-sulfamethoxazole or linezolid. It is frequently
used in combination with rifampicin for long-term treatment
of skin, soft tissue or osteoarticular infections due to
MRSA after initial in-hospital treatment with other agents
[147–150]. Clinical data to support the use of fusidic acid in
combination with other b-lactams or glycopeptides for the
treatment of staphylococcal bacteraemia, endocarditis and
osteomyelitis are very limited [148,151]. The drug can be
used topically for the treatment of acute skin infections and
for decontamination in patients colonized with MRSA [152],
particularly in settings in which mupirocin-resistant strains are
prevalent. Topical therapy, however, has been associated with
rapid emergence of resistance [153,154].
The main drawback of fusidic acid therapy is the develop-
ment of resistance in 5–15% courses of treatment when the
drug is used in monotherapy, and in much higher propor-
tions after topical use. The development of resistance is sig-
niﬁcantly lower when the drug is used in combination with
other agents [155,156].
The main side effects of fusidic acid are gastrointestinal
tract discomfort, diarrhoea, and headache. Hepatotoxicity
has been reported, and jaundice is a common manifestation.
Jaundice is reversible and mainly associated with intravenous
administration. Rarely reported side effects include granulo-
cytopenia, thrombocytopenia, and venous spasm [157–159].
Fosfomycin
Fosfomycin is a phosphonic acid derivative produced by
Streptomyces species, described in 1969 [160], that has
been used in countries such as Japan, Spain, Germany and
France for many years. Fosfomycin has an epoxide struc-
ture and a low molecular weight, and acts in the ﬁrst
stage of peptidoglycan synthesis of the bacterial wall. It has
a rapid bactericidal effect and a wide spectrum of activity,
including many MRSA strains [161–164]. Over the years, it
has maintained its activity and has shown stable rates of
resistance. It can be administered in combination (without
antagonism) with glycopeptides, linezolid, quinupristin–dalfo-
pristin, b-lactams, aminoglycosides, ansamycines, nitroimi-
dazoles, and quinolones. A tromethamine derivative can be
administered as an oral drug to treat urinary tract infec-
tions caused by some Gram-negative rods and Enterococcus
faecalis [161,165–170]. A review of the subject has been
recently published [171].
Intravenous fosfomycin has a relatively long half-life and
achieves good penetration in inﬂamed tissues, including the
aqueous and vitreous humor and the CSF. Fosfomycin does
not bind to plasma proteins and is distributed widely, reach-
ing high concentrations in interstitial ﬂuid and tissues. It is
renally excreted in its active form without metabolites and is
dialysable.
Fosfomycin has a low rate of adverse events, which
include mild gastrointestinal disturbances, phlebitis, and pain
at the injection site.
The most common infections caused by S. aureus and
treated with fosfomycin include meningitis, endophthalmitis,
postoperative infections, pneumonia, septicaemia, endocardi-
tis, and a miscellany of other infections. Unfortunately, clini-
cal information regarding the use of fosfomycin in MRSA
infections is very limited and is inadequate in several ways:
studies are retrospective, the number of reported cases is
small, and fosfomycin is frequently used in association with a
second antibacterial agent, such as an aminoglycoside, a peni-
cillin, or a cephalosporin [161,172–174].
Combinations of fosfomycin with b-lactam drugs, arbeka-
cin and other drugs have shown in vitro and in vivo synergy
against MRSA and are combinations that deserve trials [175–
179]. The main drawback of fosfomycin is the rapid develop-
ment of drug resistance.
Chloramphenicol
A very high proportion of MRSA isolates in different areas of
the world remain susceptible to chloramphenicol, including
community-acquired isolates [54,126,180–182]. In six sequen-
tial multicentre national studies of Staphylococcus performed
in Spain from 1986 to 2006, the rates of chloramphenicol
susceptibility ranged from 92% to 98% [129]. In the SENTRY
study, 82% of MRSA isolates from patients with pneumonia
were chloramphenicol-susceptible [183].
Unfortunately, the myelotoxicity of chloramphenicol and
the absence of recent reported clinical experience with it in
the treatment of MRSA infections limit its use to situations
in which no better alternatives are available. Chlorampheni-
col in association with vancomycin has shown an antagonistic
effect in vitro [184].
Synercid
Synercid is a streptogramin antimicrobial resulting from the
combination of semisynthetic pristinamycin derivatives,
quinupristin and dalfopristin, in a 3 : 7 ratio. The combination
inhibits bacterial protein synthesis at different regions of the
50S ribosomal subunit [185]. It targets both early and late
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stages of protein synthesis, resulting in synergistic activity
[186]. Synercid is active in vitro against a high proportion of
MRSA strains [187–190].
Synercid can be administered only intravenously, in a dex-
trose solution, and is eliminated mainly through bile into fae-
ces. Clearance may be slightly impaired in patients with renal
insufﬁciency.
Synercid inhibits the activity of the cytochrome P450 3A4
isoenzyme, which implies the existence of drug interactions,
especially with cyclosporine. Synercid, by interfering with the
metabolism of other drugs, may induce QTc prolongation
[191,192].
Arthralgia and myalgia are the main adverse effects of syn-
ercid, and hyperbilirubinaemia and liver toxicity may occur.
Pain and inﬂammation at the infusion site occur in up to 74%
of patients [191,193,194].
Synercid gave worse clinical results in a rabbit model of
MRSA arthritis than vancomycin alone or vancomycin plus
rifampin [195]. Synercid was equivalent to other agents for
the treatment of SSTIs, but was inferior to comparators for
the treatment of pneumonia and IE [193,196].
Synercid has not gained regulatory approval by the FDA
for the treatment of MRSA infections. The broad spectrum
of adverse effects with synercid makes it an inferior choice
for the treatment of MRSA infections.
New Glycolipopetides
Daptomycin
Daptomycin is a cyclic lipopeptide in clinical use and approved
for the treatment of complicated skin and skin structure infec-
tions and right-sided endocarditis. The drug was developed in
the early 1980s, but was initially abandoned because of con-
cerns abouty skeletal muscle toxicity [197–200].
Daptomycin is active in vitro against staphylococci, including
MRSA strains, and other Gram-positive bacteria [201–208].
Daptomycin causes a calcium-dependent rupture of the
bacterial cell membrane, resulting in a net efﬂux of potassium
that inhibits DNA, RNA, and protein synthesis. Unlike agents
that are active against the cell wall, daptomycin has rapid
bactericidal activity without cell lysis, a feature that could
reduce the release of bacterial molecules and lessen the
inﬂammatory response [209–211]. Daptomycin is available
only for intravenous administration and is highly protein-
bound (92%), with a half-life of approximately 8 h, allowing
once-daily dosing.
Daptomycin does not require dose adjustments in patients
with liver failure, but requires reduction in patients with
renal failure, and complementary dosing after haemodialysis,
because 15% of the drug is cleared after a 4-h dialysis session
[212–214].
The daily dose for adults with normal renal function is
4 mg/kg, administered once daily for SSTIs, and no less than
6–10 mg/kg for cases of bacteraemia and endocarditis.
Daptomycin is approved by the FDA for the treatment of
SSTIs caused by Gram-positive bacteria, including MRSA. Its
efﬁcacy is comparable to that of standard therapies [215–
221].
Daptomycin has been prospectively compared with stan-
dard therapy in patients with S. aureus bacteraemia and/or
right-sided endocarditis. Overall, 124 patients received 6 mg/
kg daptomycin per day, and 122 received either an antistaph-
ylococcal penicillin or vancomycin plus gentamicin. A success-
ful outcome was documented for 53 of 120 patients who
received daptomycin, as compared with 48 of 115 patients
who received standard therapy, meeting the prespeciﬁed cri-
teria for the non-inferiority of daptomycin. The success rates
were similar in patients with MRSA isolates. Daptomycin,
however, was associated with a higher rate of microbiologi-
cal failure than was standard therapy (19 vs. 11 patients,
p 0.17). Some isolates from patients with microbiological fail-
ure developed reduced susceptibility to daptomycin. Renal
dysfunction occurred more frequently in the patients receiv-
ing vancomycin than in those receiving daptomycin (26% vs.
11%) [222].
Daptomycin has been successfully used for the treatment
of bone [223–229] and joint [230] infections, but randomized
comparative trials have not been published. In a small group
of patients, decreased susceptibility to daptomycin occurred
during the treatment of bone infections [227].
Daptomycin should not be used in patients with pneumo-
nia, because of lack of efﬁcacy due to the inactivation of dap-
tomycin [231] by lung surfactant.
Resistance to daptomycin is uncommon but can be
induced by serial passage in increasing concentrations of the
antimicrobial [232]. Clinically, it has occurred in patients
who have received prolonged treatment [233,234].
Data regarding central nervous system infections are very
limited (the drug has poor activity), and daptomycin is not
approved for this indication. In vitro activity against Listeria
monocytogenes is very limited [235]. Cottagnound et al. [236]
successfully treated pneumococcal meningitis with daptomy-
cin. In a rabbit meningitis model, daptomycin displayed bacte-
ricidal activity signiﬁcantly superior to vancomycin in the
treatment of S. aureus infection. When it was given at a dose
of 6 mg/kg, the penetration of daptomycin into inﬂamed
meninges was 5%; daptomycin was therefore signiﬁcantly
more effective than vancomycin in sterilizing CSF. The level
of penetration in non-inﬂamed meninges was 2% [237]. At
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the present time, Daptomycin is not a potential alternative
for the treatment of MRSA meningitis in patients who are
not able to tolerate vancomycin.
Dalbavancin
Dalbavancin is a second-generation lipoglycopeptide with
unique pharmacokinetic properties that allow dosing once
weekly [238–240]. Dalbavancin has excellent activity against
MRSA but not against vancomycin-resistant enterococci
[241]. The drug inhibits bacterial cell wall formation by two
different mechanisms. The dosage of dalbavancin is 1000 mg,
intravenously initially, and 500 mg 7 days later.
The main clinical study with dalbavancin is an open study
on CR-BSIs caused by MSSA, MRSA and coagulase-negative
staphylococci. Infected patients who received weekly dalba-
vancin had an overall success rate that was signiﬁcantly
higher than that of those who received vancomycin. Adverse
events and laboratory abnormalities were generally mild and
comparable for the two drugs [242].
Clinical trials in cSSTIs suggest that dalbavancin is as effec-
tive as linezolid. Dalbavancin appears to be a promising new
antimicrobial for the treatment of cSSTIs but FDA approval
has been delayed [243,244].
Efﬁcacy data for other types of infection, including pneu-
monia, bone and joint infections, bacteraemia, and endocardi-
tis, are clearly needed.
Telavancin
Telavancin is another lipoglycopeptide that has a double
mechanism of action. First, it inhibits peptidoglycan chain for-
mation, blocking both transglycosylation and transpeptida-
tion. Second, telavancin alters membrane potential and
increases cellular permeability [245,246].
Telavancin is active in vitro against MRSA, including glyco-
peptide-intermediate S. aureus strains, and against the most
important Gram-positive bacteria, including VanA-type
Enterococcus. The drug has a high proportion of protein bind-
ing (93%), a high volume of tissue distribution, and a half-life
of 7–9 h [247].
Clinically, telavancin has been studied in SSTIs, with results
similar to those of comparators. In a randomized, double-
blind, phase II trial, intravenous telavancin at 10 mg/kg every
24 h was compared with standard therapy (antistaphylococ-
cal penicillin or vancomycin). Clinical success rates were sim-
ilar in all populations. Among patients with MRSA at baseline
(n = 45), clinical cure rates were 96% for telavancin and 90%
for standard therapy. Microbiological eradication was signiﬁ-
cantly better with telavancin than with standard therapy, in
particular in patients with MRSA (92% vs. 68%, p 0.04). The
incidence and severity of adverse events and laboratory
abnormalities were similar between the two groups
[248,249].
The in vitro activity of telavancin is not affected by pulmo-
nary surfactant [250], and phase III clinical trials in noso-
comial pneumonia have been completed. The ATTAIN 1 and
ATTAIN 2 studies are comparisons of telavancin and
vancomycin for hospital-acquired pneumonia due to MRSA,
but Telavancin is not yet FDA approved for the treatment of
Nosocomial Pneumonia. [250]. A phase II, randomized,
double-blind, parallel-group, multinational trial of intravenous
telavancin for the treatment of uncomplicated S. aureus
bacteraemia has also been completed.
Oritavancin
Oritavancin is another second-generation glycopeptide
undergoing phase III clinical trials. It inhibits peptidoglycan
biosynthesis at the same site as vancomycin (transglycosyla-
tion), but also forms dimers with higher afﬁnity and at lower
concentrations than vancomycin. The drug may also act as
an inhibitor of the transglycosylase enzyme [252].
Oritavancin has a spectrum of in vitro activity similar to
that of vancomycin, but is active against VanA, VanB and
VanC Enterococcus and is fully active against MRSA, including
some VRSA strains [253].
Oritavancin is available for intravenous administration
and, with no detectable metabolism, is excreted slowly and
unchanged in urine and faeces. It accumulates in tissues and
macrophages, and has a very long terminal half-life that per-
mits once-daily dosing [254,255]. The drug accumulates in
the lysosomes and is slowly liberated from them [255].
The clinical importance of this effect needs further assess-
ment.
In animal models, oritavancin has shown at least no inferi-
ority to comparators in central venous catheter infections in
rats, in a rabbit model of MRSA endocarditis, in a neutrope-
nic mouse model, and in a thigh infection model [256].
Clinical trials comparing oritavancin with vancomycin for
3–7 days for the treatment of cSSTIs (the ARRI and ARRD
studies) have shown no inferiority of oritavancin. Adverse
events in these studies had the same or a better proﬁle than
the comparators. Oritavancin has fewer cutaneous adverse
effects than vancomycin, the same nephrotoxicity as vanco-
mycin, no ototoxicity, and no QTc alterations.
Oritavancin has also been studied in patients with
S. aureus bacteraemia, excluding IE. Oritavancin once daily
(5–10 mg/kg) was compared with vancomycin or a b-lactam
antimicrobial for 10–14 days. Oritavancin was as effective as
the comparators, but had greater clinical and microbiological
success in doses of 10 mg/kg per day. Oritavancin is not yet
FDA approved.
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There is partial inhibition of oritavancin by surfactant, with
mild to moderate reduction of potency; this effect is much
less than that with daptomycin.
There is no need for oritanvancin dosage adjustment in
renal insufﬁciency or moderate hepatic insufﬁciency.
Tigecycline
Tigecycline is a new broad-spectrum tetracycline derivative
(glycylcycline) approved by the FDA in 2005. This drug is a
tetracycline analogue and the ﬁrst glycylcycline released for
clinical use.
The glycylcyclines are being developed to overcome bac-
terial mechanisms of tetracycline resistance, such as ribo-
somal protection and efﬂux pumps. This drug binds to the
30S ribosomal subunit and blocks entry of amino-acyl tRNA
into the A site of the ribosome. Tigecycline binds ﬁve times
more efﬁciently to this ribosomal site than do tetracyclines
[257,258].
Tigecycline has potent in vitro activity against a wide range
of Gram-positive and Gram-negative bacteria, including
MRSA and methicillin-resistant Staphylococcus epidermidis
[259–268].
Tigecycline can be administered only by the parenteral
route, initially in a single dose of 100 mg, and then in doses
of 50 mg every 12 h. Moderate hepatic impairment reduces
systemic clearance and prolongs the elimination half-life.
Serum concentrations are low, but the penetration of the
drug into skin blister ﬂuid, bile, gall bladder, colon, and alveo-
lar macrophages achieves concentrations greater than serum
concentrations [269–273]. Levels in bone and synovial ﬂuid
are lower than concomitant serum concentrations
[268,273,274]. Levels in the CSF with non-inﬂamed meninges
vary between 5.5% and 41% of concurrent serum concentra-
tions [273]. Biliary excretion is the primary route of elimina-
tion, and renal elimination accounts for 10–15% of the
administered drug. Tigecycline does not need reduction
in dosage in patients with renal failure, and is not dialysa-
ble. Tigecycline does not affect the cytochrome
P450 enzymes, including CYP1A2, 2C8, 2C19, 2D6, and
3A4 [271,275–279].
Tigecycline has proven non-inferiority as compared with
vancomycin plus aztreonam in the treatment of SSTIs
[280,281], but patients with necrotizing fasciitis, osteomyeli-
tis, neutropenia, gangrene, or impaired arterial blood supply
were excluded. Eradication rates for MRSA isolates were
similar between tigecycline and vancomycin–aztreonam.
Gastrointestinal adverse events with tigecycline included
nausea, vomiting, and diarrhoea. There were prolongations
of activated partial thromboplastin time and prothrombin
time in more patients treated with tigecycline than in those
treated with vancomycin–aztreonam. MRSA was isolated
from 65 patients, and treatment success rates were equiva-
lent between the treatment groups.
Tigecycline is FDA-approved for the treatment of SSII and
also for the treatment of complicated intra-abdominal infec-
tions. A pooled analysis of two international, multicentre,
non-inferiority phase III trials showed that it is not inferior
to imipenem–cilastatin in the treatment of intra-abdominal
infections [282–285], but very few patients with MRSA infec-
tions were included in these studies.
The main issue regarding the role of tigecycline in the treat-
ment of MRSA infections is its effectiveness in the treatment
of other severe infections, including nosocomial pneumonia,
bacteraemia, CR-BSIs, and bone and joint infections [286,287].
A study comparing tigecycline with imipenem–cilastatin in the
treatment of nosocomial pneumonia ended recently, but full
information is not yet available.
In a rat model of MRSA osteomyelitis, tigecycline was
compared with teicoplanin and placebo. Both reduced the
bacterial growth when compared with placebo [288].
Tigecycline was compared with vancomycin, with or with-
out rifampicin, in a rabbit model of MRSA osteomyelitis. Rab-
bits that received tigecycline and oral rifampicin (n = 14)
showed 100% infection cure; there was 90% clearance when
tigecycline was used alone. Untreated controls (n = 15) dem-
onstrated only 26% clearance [289]. Clinical data regarding
efﬁcacy of Tigecycline in human bone and joint infections are
clearly needed.
Gastrointestinal effects have been reported with tigecy-
cline. They include nausea, vomiting and diarrhoea, which
usually occur during the ﬁrst or second day of treatment,
and are generally classiﬁed as mild to moderate, not requir-
ing drug withdrawal.
Tigecycline undergoes minimal hepatic metabolism, and
thus appears to have a low potential for drug–drug
interactions.
Like tetracycline, tigecycline is a pregnancy category D
drug. Because it is structurally related to the tetracyclines, it
is considered to have similar safety concerns, such as pancre-
atitis, pseudotumour cerebri, anti-anabolic action, and photo-
sensitivity. The use of tigecycline in patients less than
18 years of age is not recommended.
Tigecycline may be considered as alternative empirical
therapy for patients with mild to moderate cSSTIs or Com-
plicated Intra Abdominal infections. It may also be used as an
alternative agent for patients who are allergic to vancomycin
or those with signiﬁcant renal impairment who have MRSA
infections.
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Anti-MRSA b-Lactam Drugs
Ceftobiprole
The classic concept that an MRSA isolate was an isolate with
cross-resistance to all other b-lactam drugs is no longer
true. Several new b-lactam agents are undergoing clinical tri-
als, and will soon be added to the therapeutic armamentar-
ium for MRSA infections.
Ceftobiprole is a new cephalosporin administered intrave-
nously, with broad-spectrum in vitro activity. It is character-
ized by a strong afﬁnity for penicillin-binding protein (PBP)2a
and PBP2x, which are responsible for resistance in Staphylo-
coccus spp. and Streptococcus pneumoniae, respectively. It is
active against Gram-negative bacteria, including a high pro-
portion of Pseudomonas aeruginosa strains, and against Gram-
positive bacteria, including MRSA [290–292]. Ceftobiprole
activity against MRSA includes both community and nosoco-
mially acquired isolates [293–295].
Ceftobiprole medocaril administered intravenously is con-
verted almost completely to the active drug, ceftobiprole. Cef-
tobiprole binds minimally (16%) to plasma proteins, undergoes
minimal hepatic metabolism, and is rapidly eliminated, primarily
unchanged, by renal excretion. The terminal elimination half-
life is 3 h, and the predominant mechanism responsible for
elimination is glomerular ﬁltration. Ceftobiprole does not sig-
niﬁcantly induce or inhibit relevant cytochrome P450 enzymes,
and is neither a substrate for nor an inhibitor of P-glycopro-
tein. The pharmacokinetics of ceftobiprole are linear following
single and multiple infusions of 125–1000 mg [292,296,297].
In patients with moderate to severe renal impairment,
dose adjustments for the treatment of infections caused by
target pathogens, including MRSA, should be based on creati-
nine clearance [296].
In a multicentre, multinational, double-blind, randomized
trial concerning treatment of cSSTIs caused by Gram-positive
bacteria, ceftobiprole (500 mg every 12 h) was compared
with vancomycin (1 g every 12 h). Overall, 93% of those
treated with ceftobiprole and 93% of those treated with
vancomycin were cured. The cure rates for patients with
MRSA infections were 91.8% (56/61) with ceftobiprole treat-
ment and 90.0% (54/60) with vancomycin treatment. Only
4% of patients treated with ceftobiprole required drug dis-
continuation because of adverse events [298].
Ceftobiprole is undergoing clinical evaluation in animal
models of respiratory tract infection [299] and in human tri-
als. A study comparing ceftobiprole with ceftriaxone in
patients with CAP has been completed. Two phase III trials
concerning nosocomial pneumonia have been completed.
They included both patients with VAP and non-VAP cases.
The results were not uniform in both groups, or in all age
strata, but ﬁnal reports are pending.
A trial assessing the role of ceftobiprole in the treatment
of hospitalized patients with S. aureus bacteraemia was with-
drawn prior to recruitment.
A study of the effectiveness of ceftobiprole treatment of
patients with fever and neutropenia has been suspended
because of the FDA medwatch on the comparator drug,
cefepime.
Ceftaroline
Ceftaroline is a novel cephalosporin with broad-spectrum
activity against Gram-negative and Gram-positive pathogens.
The antimicrobial activity of ceftaroline is similar to that of
ceftriaxone, with one major difference: ceftaroline is also
very potent against MRSA [300–302].
A randomized, observer-blinded study to evaluate the
safety and efﬁcacy of ceftaroline vs. standard therapy in adult
patients with complicated skin and skin structure infections
showed a clinical cure rate of 96.7% (59/61) for ceftaroline
vs. 88.9% (24/27) for standard therapy. The microbiological
success rate was 95.2% (40/42) for ceftaroline vs. 85.7% (18/
21) for standard therapy. Most adverse events resulting from
ceftaroline were mild and not related to treatment [303].
Using the rabbit endocarditis model, ceftaroline was com-
pared with linezolid and vancomycin against MRSA. After a
4-day treatment, ceftaroline exhibited superior bactericidal
in vivo activity against MRSA strains, and appeared to be the
most effective drug against a heterogeneous glycopeptide-
intermediate S. aureus strain [304].
Currently, ceftaroline is being compared with ceftriaxone
in two clinical trials involving adults with CAP.
Carbemenems
Carbamenems may also impact on the treatment of MRSA
infections. Tomopenem (formerly CS-023) is a novel
1b-methylcarbapenem with a broad-spectrum coverage of
Gram-positive and Gram-negative pathogens. The MICs of
tomopenem for MRSA and P. aeruginosa at which 90% of the
isolates tested were inhibited were 8 and 4 mg/L, respec-
tively, and were ‡four-fold lower than those of imipenem and
meropenem. The antibacterial activity of tomopenem against
MRSA was correlated with a higher afﬁnity for PBP2a [305].
Other Potential New Drugs
Iclaprim (formerly AR-100, Ro 48-2622) is a diaminopyrimi-
dine dihydrofolate reductase inhibitor [306–309]. This com-
pound is active against Gram-positive bacteria, including
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Enterococus spp. and MRSA, VISA, VRSA and macrolide-resis-
tant, quinolone-resistant, and trimethoprim-resistant strains.
In addition, iclaprim has demonstrated activity against
Streptococcus pneumoniae, including penicillin-resistant, eryth-
romycin-resistant, levoﬂoxacin-resistant, and trimethoprim–
sulphamethoxazole-resistant strains. Furthermore, it has
in vitro activity against Gram-negative bacteria and atypical
bacteria [310,311].
Iclaprim is highly synergistic with sulphamethoxazole and
sulphadiazine, and is neither synergistic nor antagonistic with
macrolides, lincosamides, aminoglycosides, quinolones, b-lac-
tams, trimethoprim, tetracyclines, and glycopeptides [312].
Iclaprim is available for intravenous and oral use, with very
good oral bioavailability. Oral iclaprim undergoes rapid absorp-
tion and is subject to presystemic metabolism. Both intrave-
nous and orally administered iclaprim undergo complete
biotransformation, and the excretion of metabolites is pre-
dominantly in the urine (Brandt et al., 47th ICAAC, 2007,
Abstract A–804).
Phase II clinical trials have shown promise for use in cSS-
TIs that are caused by MRSA, and two phase III clinical trials
have been recently completed for the same indication.
Two studies of iclaprim in cSSTIs have been completed.
The ASSIST-1 trial was a phase 3 safety and efﬁcacy study of
intravenous iclaprim vs. linezolid in cSSTI. The ASSIST-2
study evaluated intravenous iclaprim vs. linezolid in cSSTIs.
Iclaprim successfully met its primary endpoints, namely
non-inferiority in clinical cure rates vs. linezolid and vanco-
mycin. Iclaprim is not FDA approved at the time of writing
(November 2009).
Currently, iclaprim is undergoing clinical trials concerning
hospital-acquired VAP and other forms of nosocomial pneu-
monia.
Teﬁbazumab (Aurexis) is a humanized monoclonal anti-
body that binds to the surface-expressed adhesion protein
clumping factor A [313]. It is under development as adjunc-
tive therapy for serious S. aureus infections, but additional
trials are warranted to address the dosing range and efﬁcacy
of teﬁbazumab [315].
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